PATENT ABSTRACTS a05

4735896 4736018

S Y N T H E T I C P E P T I D E A N D P R O C E S S O F U S I N G S A M E F O R

T H E D E T E C T I O N A N D D I A G N O S I S O F A I D S A N D

P R E - A I D S C O N D I T I O N S

Chang Y Wang, James J G Wang assigned to United Biomedical Inc

B L O O D C O A G U L A T I O N I N H I B I T I N G P R O T E I N S ,

P R O C E S S E S F O R P R E P A R I N G T H E M A N D T H E I R U S E S

Christian P M Reutelingsperger, Maastricht, Netherlands assigned to Boehringer Ingelheim International GmbH

The present invention relates to a method for the detection and diagnosis of AIDS (acquired im- mune deficiency syndrome) ARC (AIDS Related Complex) and pre-AIDS conditions in body fluids by the use of a chemically syn- thesized peptide. The peptide has an amino acid sequence corresponding to a segment of the en- velope protein, p41, of HTLV-III and has been found to be highly immunoreactive with anti- bodies in sera of patients with AIDS, ARC and pre-AIDS conditions. More specifically, the pre- sent invention is directed to the use of a chem- ically synthesized peptide containing therein a segment of about twenty-one (21) amino acids, or their analogues, in a prescribed sequence for the detection of antibodies to the HTLV-III virus in human body fluids of AIDS, ARC or pre-AIDS patients. The detection method in- cludes an enzyme-linked immunosorbent assay (ELISA), an immunoradiometric assay (IRMA), and other forms of immuno assay pro- cedures such as enzyme immuno blotting assay on nitrocellulose paper and hemagglutination assay using the peptide as the antigen. The pre- ferred detection method is ELISA. The present invention also relates to a vaccine and a method for generating antibodies to HTLV-III in healthy mammals, including humans by the use of the chemically synthesized 21mer peptide or its analogues.

4736017

C H E M I C A L L Y D E F I N E D V A C C I N E A G A I N S T U R I N A R Y

I N F E C T I O N S

Peter O'Hanley, Gary K Schoolnik, David Lark, Stanley Falkow assigned to The Board of Trustees of the Leland Stanford Junior Univer- sity

A vaccine effective in protecting mammals against urinary infections is prepared from purified Gal-Gal pilus proteins or fragments thereof.

This invention discloses proteins which inhibit the coagulation of the blood, processes for pre- paring these proteins, and the use thereof.

4737363

B A C T E R O I D E S N O D O S U S V A C C I N E

David J Stewart, Alexander Kortt, Hawthorn East, Australia assigned to Commonwealth Scientific and Industrial Research Organization

A vaccine for use in the prevention or treatment of foot-rot comprises an immunologically effec- tive amount of at least one protease, particularly an extracellular serine protease, of Bacteroides nodosus as an active component thereof, and op- tionally an acceptable pharmaceutical or veterinary carrier therefor.

4737579

M O N O C L O N A L A N T I B O D I E S F O R H U M A N N O N - S M A L L C E L L

L U N G C A R I N O M A S

lngegerd Hellstrom, Joseph P Brown, Karl E Hellstrom, Diane Horn, Peter Linsley assigned to Oncogen

The present invention is concerned with novel monoclonal antibodies which define antigens as- sociated with human non-small cell lung car- cinomas ( NSCLC ). The antibodies bind to normal human cells to a lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods.